PureTech Health (GB:PRTC) has released an update.
PureTech Health, a clinical-stage biotherapeutics company focused on developing treatments for devastating diseases, has successfully passed a Special Resolution during its General Meeting, approving a tender offer to purchase around 33.5 million of its ordinary shares at 250 pence each. Shareholders showed overwhelming support with 99.94% voting in favor. The offer’s results will be publicized on June 24, 2024, following the closing deadlines for Tender Forms and ADS Letters of Transmittal on June 20 and June 18, respectively.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
